Prediction of the efficacy of bevirimat used for the treatment of HIV infection in Russia


Cite item

Full Text

Abstract

The nucleotide sequences coding the CA-SP1 Pr55gag in 61 samples of HIV-1 subtype A variant IDU-A isolated in Russia were analyzed for bevirimat resistance mutations (CA-H226V, CA-L231F, CA-231M, SP1-A1V, SP1-A3T, SP1-A3V) and for polymorphisms in the GAG CA-SP1 cleavage site. None of the six bevirimat resistance mutations was found in the sequences analyzed. There were three polymorphisms CA-G225S, CA-R229K, CA-V2301 and a high variability in the C-terminus of SP1. The substitution SP-T8Q was observed in 98% of cases, which could probably affect the clinical efficacy of bevirimat. Therefore bevirimat can be potentially active in Russian patients infected with IDU-A variant, but strain-specific polymorphisms in combination with other virus genome mutations can influence the efficiency of bevirimat treatment.

References

  1. Бобков А. Ф., Казеннова Е. В., Бобкова М. Р. и др. Молекулярно-эпидемиологическая характеристика ВИЧ-1 на территории России // Вестн. РАМН. - 2002. - № 8. - С. 40-42.
  2. Adamson C., Ablan S., Boeras I. et al. In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat) // J. Virol. - 2006. - Vol. 80. - P. 10957- 10971.
  3. Bobkova M. R., Kazennova E. V., Selimova L. M. et al. Serological approaches to subtyping of HIV-1 in injecting drug users in Russia: evidence of subtype homogeneity at the main sites of the epidemic // Int. J. STD AIDS. - 2001. - Vol. 12. - P. 34- 40.
  4. Calazans A., Brindeiro R., Brindeiro P. et al. Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism // J. Infect. Dis. - 2005. - Vol. 191. - P. 1961-1970.
  5. De Oliveira T., Engelbrecht S., Janse van Rensburg E. et al. Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness? // J. Virol. - 2003. - Vol. 77. - P. 9422-9430.
  6. Dobard Ch. W., Briones M. S., Chow S. A. Molecular mechanisms by which human immunodeficiency virus type 1 integrase stimulates the early steps of reverse transcription // J. Virol. - 2007. - Vol. 81. - P. 10037-10046.
  7. Esté J. A., Telenti A. HIV entry inhibitors // Lancet. - 2007. - Vol. 370. - P. 81-88.
  8. Gonzalez L. M., Santos A. F., Abecasis A. B. et al. Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates // J. Antimicrob. Chemother. - 2008. - Vol. 61. - P. 1201-1204.
  9. Heyndrickx L., Janssens W., Zekeng L. et al. Simplified strategy for detection of recombinant human immunodeficiency virus type 1 group M isolates by gag/env heteroduplex mobility assay // J. Virol. - 2000. - Vol. 74. - P. 363-370.
  10. Imamichi T. Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors // Curr. Pharm. Des. - 2004. - Vol. 10. - P. 4039-4053.
  11. Li F., Zoumplis D., Matallana C. et al. Determinants of activity of the HIV-1 maturation inhibitor PA-457 // Virology. - 2006. - Vol. 356. - P. 217-224.
  12. Malet I., Wirden M., Derache A. Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patents // AIDS. - 2007. - Vol. 23. - P. 871-873.
  13. Parniak M. A., Sluis-Cremer N. Inhibitors of HIV-1 reverse transcriptase // Adv. Pharmacol. - 2000. - Vol. 49. - P. 67- 109.
  14. Salzwedel K., Martin D. E., Sakalian M. Maturation inhibitors: a new therapeutic class targets the virus structure // AIDS Rev. - 2007. - Vol. 9. - P. 162-172.
  15. Salzwedel K., Reddick M., Matallana C. et al. Role of Gag polimorphisms in HIV-1 sensitivity to the maturation inhibitor bevirimat // Antivirol. Ther. - 2008. - Vol. 13. - Suppl. 3. - A31.
  16. Smith P. F., Ogundele A., Forrest A. et al. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl) betulinic acid (bevirimat) against human immunodeficiency virus infection // Antimicrob. Agents Chemother. - 2007. - Vol. 51. - P.3574-3581.
  17. Van Baelen K., Salzwedel K., Rondelez E. et al. Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1 // Antimicrob. Agents Chemother. - 2009. - Vol. 53. - P. 2185-2188.
  18. Yebra G., Holguin A. The maturation inhibitor bevirimat (PA-457) can be active in patients carrying HIV type-1 non-B subtypes and recombinants // Antivirol. Ther. - 2008. - Vol. 13. - P. 1083-1085.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Kazennova E.V., Vasil'ev A.V., Bobkova M.R., Kazennova E.V., Vasilyev A.V., Bobkova M.R.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-77676 от 29.01.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies